Spectral Medical Inc. provided an update for the month of November on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. 79 patients enrolled to date and continuing to close in on the interim target of 90 patients, an important milestone as the Company's strategic commercial partner, Baxter will have the opportunity to view the data as well as provide a second milestone payment to Spectral. Currently 20 Tigris trial sites, with near term onboarding of new, high quality clinical sites.

Crude mortality results at both 28-day (primary endpoint) and at 1-year, thus far, continue to exceed efficacy targets.